secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2026-09-29T11:33:10+00:00
Accession:  0001453687-26-000105
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Cartesian's Descartes-08 retreatment cuts MG-ADL 6.6 points at Month 12; no new safety signals; Phase 3 AURORA data 1Q27
--------------------------------------------------------------------------------

- In 5 retreated MG patients, mean MG-ADL fell 6.6 (±4.2) points and MGC fell 15 (±6.2) points from baseline at Month 12 after retreatment.
- Median time from initial treatment completion to first retreatment was 16.6 months; all patients had clinically meaningful MGC (≥3) and MG-ADL (≥2) reductions.
- No serious adverse events during retreatment; no cases of CRS, ICANS, cytopenias, or hypogammaglobulinemia; adverse events were transient and mild.
- Phase 3 AURORA topline data expected 1Q27; BLA filing in MG expected mid-2027; Descartes-08 has RMAT and Orphan Drug designations and FDA SPA agreement.
- Patients had mean disease duration of 13 years and extensive prior treatment histories.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/0001453687-26-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/rnac-20260929.htm
  HTML page:      https://secwatch.observer/filing/0001453687-26-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer